Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center

Purpose: The goal of this study was to assess the potential real-world effect of the recently reported SC.24 trial on spine stereotactic body radiation therapy (SBRT) utilization. We estimated the proportion of patients treated with conventional radiation therapy (CRT) who would have been eligible f...

Full description

Bibliographic Details
Main Authors: Andrew J. Arifin, MD, Sympascho Young, MD, Glenn S. Bauman, MD, Hatim Fakir, PhD, Belal Ahmad, MD, Joanna M. Laba, MD, George B. Rodrigues, MD, PhD, Eric K. Nguyen, MD, Arjun Sahgal, MD, Timothy K. Nguyen, MD, FRCPC
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109423000490
_version_ 1797845655746510848
author Andrew J. Arifin, MD
Sympascho Young, MD
Glenn S. Bauman, MD
Hatim Fakir, PhD
Belal Ahmad, MD
Joanna M. Laba, MD
George B. Rodrigues, MD, PhD
Eric K. Nguyen, MD
Arjun Sahgal, MD
Timothy K. Nguyen, MD, FRCPC
author_facet Andrew J. Arifin, MD
Sympascho Young, MD
Glenn S. Bauman, MD
Hatim Fakir, PhD
Belal Ahmad, MD
Joanna M. Laba, MD
George B. Rodrigues, MD, PhD
Eric K. Nguyen, MD
Arjun Sahgal, MD
Timothy K. Nguyen, MD, FRCPC
author_sort Andrew J. Arifin, MD
collection DOAJ
description Purpose: The goal of this study was to assess the potential real-world effect of the recently reported SC.24 trial on spine stereotactic body radiation therapy (SBRT) utilization. We estimated the proportion of patients treated with conventional radiation therapy (CRT) who would have been eligible for spine SBRT per trial inclusion criteria and analyzed the potential estimated increased costs to our institution. Methods and Materials: This was a retrospective review of patients who received spine CRT at our institution between August and October 2020. Data abstracted included demographics, SC.24 eligibility criteria, provider-reported pain response, and survival. A cost analysis and time survey was performed using institutional and provincial data. Results: Of 73 patients reviewed, 24 patients (33%) were eligible. The most common exclusion factors included irradiation of ≥3 consecutive spinal segments (n = 32, 44%), Eastern Cooperative Oncology Group performance status >2 (n = 17, 23%), and symptomatic spinal cord compression (n = 13, 18%). Of eligible patients, the mean age was 68.92 years, median spinal instability in neoplasia score was 8 (interquartile range, 7-9), and median Eastern Cooperative Oncology Group performance status was 2 (interquartile range, 1-2). The most common primary cancer types among eligible patients were lung (n = 10) and breast (n = 4). The median survival of eligible patients was 10 months (95% confidence interval, 4 months to not reached) with 58% surviving longer than 3 months. Of patients who had subjective pain documented after CRT, 54% had at least some response. The cost of spine SBRT was estimated at CA$4764.80 compared with $3589.10 for CRT, and tasks for spine SBRT took roughly 3 times as long as those for CRT. Conclusions: One-third of patients who received palliative spine CRT met eligibility criteria for SC.24. This possible expanded indication for spine SBRT can have a substantial effect on resource utilization. These data may be useful in guiding resource planning at institutions looking to commence a spine SBRT program.
first_indexed 2024-04-09T17:42:31Z
format Article
id doaj.art-20a6e337d7c143a7b5fc88c830acec0f
institution Directory Open Access Journal
issn 2452-1094
language English
last_indexed 2024-04-09T17:42:31Z
publishDate 2023-09-01
publisher Elsevier
record_format Article
series Advances in Radiation Oncology
spelling doaj.art-20a6e337d7c143a7b5fc88c830acec0f2023-04-17T04:07:19ZengElsevierAdvances in Radiation Oncology2452-10942023-09-0185101220Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer CenterAndrew J. Arifin, MD0Sympascho Young, MD1Glenn S. Bauman, MD2Hatim Fakir, PhD3Belal Ahmad, MD4Joanna M. Laba, MD5George B. Rodrigues, MD, PhD6Eric K. Nguyen, MD7Arjun Sahgal, MD8Timothy K. Nguyen, MD, FRCPC9Division of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, CanadaDepartment of Radiation Oncology, Walker Family Cancer Centre, St. Catharines, Ontario, CanadaDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada; Corresponding author: Timothy K. Nguyen, MD, FRCPCPurpose: The goal of this study was to assess the potential real-world effect of the recently reported SC.24 trial on spine stereotactic body radiation therapy (SBRT) utilization. We estimated the proportion of patients treated with conventional radiation therapy (CRT) who would have been eligible for spine SBRT per trial inclusion criteria and analyzed the potential estimated increased costs to our institution. Methods and Materials: This was a retrospective review of patients who received spine CRT at our institution between August and October 2020. Data abstracted included demographics, SC.24 eligibility criteria, provider-reported pain response, and survival. A cost analysis and time survey was performed using institutional and provincial data. Results: Of 73 patients reviewed, 24 patients (33%) were eligible. The most common exclusion factors included irradiation of ≥3 consecutive spinal segments (n = 32, 44%), Eastern Cooperative Oncology Group performance status >2 (n = 17, 23%), and symptomatic spinal cord compression (n = 13, 18%). Of eligible patients, the mean age was 68.92 years, median spinal instability in neoplasia score was 8 (interquartile range, 7-9), and median Eastern Cooperative Oncology Group performance status was 2 (interquartile range, 1-2). The most common primary cancer types among eligible patients were lung (n = 10) and breast (n = 4). The median survival of eligible patients was 10 months (95% confidence interval, 4 months to not reached) with 58% surviving longer than 3 months. Of patients who had subjective pain documented after CRT, 54% had at least some response. The cost of spine SBRT was estimated at CA$4764.80 compared with $3589.10 for CRT, and tasks for spine SBRT took roughly 3 times as long as those for CRT. Conclusions: One-third of patients who received palliative spine CRT met eligibility criteria for SC.24. This possible expanded indication for spine SBRT can have a substantial effect on resource utilization. These data may be useful in guiding resource planning at institutions looking to commence a spine SBRT program.http://www.sciencedirect.com/science/article/pii/S2452109423000490
spellingShingle Andrew J. Arifin, MD
Sympascho Young, MD
Glenn S. Bauman, MD
Hatim Fakir, PhD
Belal Ahmad, MD
Joanna M. Laba, MD
George B. Rodrigues, MD, PhD
Eric K. Nguyen, MD
Arjun Sahgal, MD
Timothy K. Nguyen, MD, FRCPC
Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
Advances in Radiation Oncology
title Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
title_full Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
title_fullStr Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
title_full_unstemmed Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
title_short Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center
title_sort planning for the effect of the sc 24 trial on spine stereotactic body radiation therapy utilization at a tertiary cancer center
url http://www.sciencedirect.com/science/article/pii/S2452109423000490
work_keys_str_mv AT andrewjarifinmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT sympaschoyoungmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT glennsbaumanmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT hatimfakirphd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT belalahmadmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT joannamlabamd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT georgebrodriguesmdphd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT ericknguyenmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT arjunsahgalmd planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter
AT timothyknguyenmdfrcpc planningfortheeffectofthesc24trialonspinestereotacticbodyradiationtherapyutilizationatatertiarycancercenter